Tepezza Settlement Amounts: What Determines Case Value

There is no finalized Tepezza settlement. No case has gone to trial. Anyone who tells you what your case is worth today is guessing.

What can be said with confidence is where the litigation stands, what a settlement would likely look like structurally, and which factors will drive individual case values when a framework emerges.

Where Settlement Actually Stands — July 2026

Confirmed:

• 277 cases are pending in MDL 3079 before Judge Thomas Durkin in the Northern District of Illinois.
• In August 2024, Magistrate Judge M. David Weisman ordered the parties into quarterly settlement conferences. Those talks have now been running for roughly two years.
• On October 1, 2025, Chief Magistrate Judge Weisman held an off-the-record conference with counsel for both sides and struck every deadline in the bellwether trial program. The first trial came off the calendar.
• No claims were dismissed in the process. No expert was excluded. No summary judgment was entered against plaintiffs. The trials simply stopped being prepared.
• Trial deadlines remain suspended.

Not confirmed: any settlement, any settlement amount, any timeline for one.

The distinction matters, and be skeptical of any firm that blurs it.

Why the Trial Suspension Is Read as a Settlement Signal

Bellwether trials are expensive. Preparing four of them means expert depositions, Rule 702 briefing, summary judgment motions, pretrial conferences, and trial teams — millions of dollars per side.

Courts do not clear that calendar casually. When trial dates come off in a mass tort without any accompanying ruling that weakened the plaintiffs' cases, the standard interpretation among practitioners is that both sides are far enough into settlement discussions that continued trial preparation would be money burned.

That is exactly the posture here: two years of court-ordered quarterly negotiations, followed by a private conference, followed by a cleared trial calendar, with the claims all still intact.

It is a signal. It is not a guarantee. Settlement talks in mass torts do fail, and if these do, the bellwether program can be reinstated or cases can be remanded to plaintiffs' home federal districts for individual trials.

Why This MDL's Small Size May Work in Claimants' Favor

Most people assume a bigger mass tort means bigger recoveries. Frequently the opposite is true.

At 277 cases, Tepezza is unusually small for a pharmaceutical MDL — compare it to litigations with tens of thousands of claims. Two consequences follow:

Settlement is more affordable for the defendant. A resolution here does not require the reserves a mass tort with 20,000 claimants would. For Amgen, which acquired Horizon for $27.8 billion in 2023, resolving an inherited liability of this size is a manageable number against the value of clearing it off the books.

The settlement fund is divided fewer ways. In a global settlement, the per-claimant share depends heavily on how many claimants there are. A smaller claimant pool with strong liability evidence generally produces higher individual values than a large pool with mixed evidence.

Multiple plaintiffs' firms following this litigation have made this observation publicly, and it is one reason the litigation has attracted attorney interest disproportionate to its size.

What Will Drive Your Individual Case Value

Global settlements in pharmaceutical litigation are almost always structured as tiered matrices: claims are scored against defined criteria and slotted into value bands. The factors below are what those matrices typically weigh.

1. Severity and permanence of the hearing injury

The single biggest driver. Anticipated ordering, highest to lowest:

• Profound or total hearing loss requiring cochlear implantation
• Severe bilateral sensorineural hearing loss requiring hearing aids
• Moderate permanent hearing loss, documented by audiogram
• Permanent, constant, disabling tinnitus
• Moderate persistent tinnitus, autophony, or ear-plugging
• Symptoms that fully resolved after infusions stopped

2. Objective audiological documentation

This is what separates a well-positioned claim from a contested one. A baseline audiogram before Tepezza compared against post-treatment testing showing measurable decline is the strongest evidence available in this litigation. Post-treatment audiometry alone still carries substantial weight. Purely subjective symptom reports with no testing are the hardest to value.

If you have not seen an audiologist and you have symptoms, get tested — for your health first, and because it strengthens any claim second.

3. When you were treated

Infusions completed before July 17, 2023 present the cleanest failure-to-warn case: the label at that time said nothing about permanent hearing loss and recommended no hearing monitoring. Treatment after the label change is not disqualifying, but raises additional factual questions about what your prescriber knew and told you.

4. Contemporaneous medical documentation

Records showing you reported hearing changes to a physician or infusion nurse during or shortly after treatment do significant work on causation. A gap of years between the last infusion and the first documented complaint invites a defense argument about alternative causes.

5. Age and life expectancy

A 42-year-old facing five decades with permanent hearing loss has substantially greater damages than a claimant with the same audiogram at 78. This is a standard feature of injury valuation across all litigation.

6. Occupational and economic impact

Documented lost income, career change, reduced hours, or diminished earning capacity — especially for people whose work depends on hearing: teachers, physicians and nurses, musicians, attorneys, tradespeople, customer-facing and sales roles.

7. Documented economic damages

Hearing aids (often $2,000–$8,000 per pair, frequently uncovered by insurance, replaced every few years), cochlear implant surgery and mapping, tinnitus retraining therapy, ongoing audiology visits, assistive listening devices. Keep every receipt.

8. Non-economic damages

In pharmaceutical litigation these frequently exceed the economic figures. Social withdrawal, inability to hear family members, sleep destroyed by tinnitus, anxiety and depression secondary to hearing loss, loss of enjoyment of music and conversation — these are real, compensable, and heavily weighted. Some states cap non-economic damages, which is one reason where you were treated affects value.

9. Pre-existing hearing conditions

Prior hearing loss doesn't bar a claim, but the defense will argue about how much of your current condition Tepezza actually caused. Documentation showing measurable worsening is what answers that.

10. Continued use after the warning

Worth noting candidly: in prior pharmaceutical litigations, claimants who continued using a drug after a warning was added have sometimes seen reduced valuations. This should never drive a medical decision. Talk to your doctor about your treatment; your health comes first.

OPTIONAL SECTION — Publicly Published Estimates

(Delete this entire section if Robert prefers no dollar figures. If retained, keep the framing and disclaimer exactly as written.)

Other firms tracking this litigation have published their own estimates of potential Tepezza case values, generally falling in ranges from the low six figures up to $500,000 or more for the most severe injuries, with the strongest cases — profound permanent loss in younger claimants — projected higher.

Baker Legal Team does not adopt, endorse, or predict any of these figures. They are estimates published by third parties before any settlement exists or any case has been tried. No settlement has been reached, no matrix has been established, and no one can tell you today what your case will be worth. Any lawyer who quotes you a number for your specific case right now is not being straight with you.

What a Settlement Timeline Would Realistically Look Like

If a global settlement is announced, money does not move immediately. The typical sequence:

1. Framework announced — the parties agree on total value and structure.
2. Matrix and criteria finalized — injury tiers, required proof, points system.
3. Participation threshold — defendants usually require a high percentage of claimants to opt in before the deal binds.
4. Claim submission — each claimant submits medical records, audiograms, and proof of infusion.
5. Scoring and administration — a settlement administrator evaluates and tiers each claim.
6. Liens resolved — Medicare, Medicaid, and private insurer reimbursement claims must be satisfied.
7. Distribution — payments issue.

Realistically, this runs 6 to 18 months from announcement to first checks. Claims filed before a settlement is announced move through this pipeline first; claims filed at the last minute or afterward face the longest waits and the greatest eligibility risk.

Amgen Is the Defendant Now

Amgen completed its acquisition of Horizon Therapeutics for $27.8 billion in October 2023, after resolving an FTC challenge, and assumed the Tepezza litigation with it.

This is good for claimants. Amgen is one of the largest biotechnology companies in the world — a defendant with the balance sheet to fund a resolution and a clear institutional interest in clearing an inherited liability rather than trying four consecutive jury trials over a drug it didn't develop.

The Practical Point

You cannot control the settlement amount. You can control two things:

Whether your claim exists when a framework is announced. Settlement programs are built around the claims that exist at that moment. Filing later is the most common way people end up outside a resolution entirely.

How well documented your claim is. Audiograms, medical records reflecting your complaints, receipts for hearing aids and treatment, documentation of work impact. The stronger your file, the higher your tier.

Get Your Case Reviewed

[FREE CASE REVIEW] · [CALL 800-356-4338]

Free nationwide consultation, 24/7. No fees unless you win.

ATTORNEY ADVERTISING. No settlement has been reached in the Tepezza litigation. Prior results do not guarantee or predict a similar outcome in any future case. Nothing on this page is a promise, guarantee, or prediction of any particular result. Every case is different and must be evaluated on its own facts.